Kate Cwynarski

TL;DR: The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.

TL;DR: These guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection and at community advocates responsible for promoting the best interests and care of HIV-positive adults.

TL;DR: The analysis of the response to treatment with donor lymphocyte infusions (DLI) and the survival in 66 consecutive patients who relapsed after primary treatment by allogeneic stem cell transplantation for BCR-ABL–positive chronic myeloid leukemia concludes that the majority of molecular remissions after DLI are durable, and thus the most of responding patients may prove to have been cured.

TL;DR: The results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT) as an alternative to whole-brain radiotherapy (WBRT) as consolidation after high-dose-methotrexate-based chemoimmunotherapy were reported.

TL;DR: The aim of this monograph is to provide a chronology of key events and milestones in the development of HIV/AIDS-related cancers over a 12-month period from 1989 to 2002, and to promote awareness of the importance of timely diagnosis and ART.